Navigation Links
Sofinnova Raises $500 Million Biotech Venture Fund
Date:7/23/2014

MENLO PARK, Calif., July 23, 2014 /PRNewswire/ -- Sofinnova Ventures, a Menlo Park based investment firm, today announced the closing of Sofinnova Venture Partners IX, L.P. at the hard cap of $500 million and in excess of the initial fund target of $425 million.

Sofinnova focuses exclusively on helping entrepreneurs build successful biotechnology companies. Consistent with recent funds, SVP IX will provide capital primarily to companies with promising later stage clinical programs, along with select investments in earlier stage opportunities. Investments will focus on developing specialty pharmaceuticals and orphan disease products. Sofinnova intends to continue the firm's successful strategy of sourcing investments in both the United States and Europe.

"We value the support that our returning limited partners and new investors have shown for our strategy and the Sofinnova team," commented Jim Healy, General Partner, Sofinnova. "Sofinnova is proud to partner with talented entrepreneurs who are focused on developing innovative medicines that can positively impact patient care. We remain committed to working with our collective network to identify and develop important new drugs, build successful companies, and continue to generate significant returns for our investors."

Sofinnova recent IPOs and exits include Labrys (acquired by Teva), ZS Pharma (IPO, ZSPH), Versartis (IPO, VSAR), Aerie (IPO, AERI), Tesaro (stock sale, TSRO), SARcode (acquired by Shire), NextWave (acquired by Pfizer), Intellikine (acquired by Takeda), Hyperion (IPO, HPTX), Durata (IPO, DRTX), Amarin (stock sale, AMRN),  Vicept (acquired by Allergan) and Preglem (acquired by Gedeon Richter).

The partners of SVP IX are Srini Akkaraju, MD, PhD, Jim Healy, MD, PhD, Anand Mehra, MD, Mike Powell, PhD, Lars Ekman, MD, PhD, David Kabakoff, PhD and Jay Shepard.

About Sofinnova Ventures

Sofinnova Ventures has over 40 years of experience building life science companies into market leaders. With $1.8 billion in committed capital, the firm applies capital and expertise to take companies from inception to exit. Sofinnova's investment team of MDs, PhDs and seasoned executives has significant scientific, operational and strategic experience, and specializes in financing clinical therapeutics. Our team partners with entrepreneurs to build successful companies, advance medicine and address patients' unmet medical needs.

Sofinnova is headquartered in Menlo Park, CA with offices in La Jolla, CA and Dublin, Ireland. www.sofinnova.com.

Contact Information:
Jennifer James
Partner – Investor Relations and Marketing
Sofinnova Ventures
(650) 681-8429; Jennifer@sofinnova.com

Logo - http://photos.prnewswire.com/prnh/20130724/SF52046LOGO-b


'/>"/>
SOURCE Sofinnova Ventures
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Edico Genome Raises $10 Million in Series A Financing to Commercialize DRAGEN Chip to Overcome Sequencing Data Analysis Bottleneck
2. Tute Genomics Raises $1.5M for Cloud-based Genome Analytics & Machine-learning for Gene Discovery
3. Curoverse Raises $1.5 Million to Build Open Source Platform for Genomic and Biomedical Big Data
4. The Holistic Sanctuary Raises Alarm About Teenage Drug Addiction
5. Immune Design Raises Up to $49 Million Series C Financing
6. Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
7. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
8. Advanced Animal Diagnostics Raises $6 Million for On-farm Diagnostics
9. OriGene Technologies Raises $21.3 Million in Series C Funding
10. Z Trim Holdings Announces Conclusion of Successful Warrant Exercise Program: Raises $2.195 Million
11. Strand Raises Series B From Burrill & Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... ... NYC , the sensor and data driven conferences, will take place on June 7-8, 2016, at ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... and IVF laboratories. A contingency of reproductive endocrinologists, including Dr. George Hill ... experiencing infertility and to help them build families. , Ovation Fertility is a ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... the pre-launch success of their revolutionary, veterinarian-designed product for indoor cats. The NoBowl ... and play with their food the way nature intended. NoBowls make cats happy ...
(Date:4/29/2016)... , April 29, 2016 ... by Transparency Market Research "Separation Systems for Commercial ... Growth, Trends, and Forecast 2015 - 2023", the ... at US$ 10,665.5 Mn in 2014 and is ... from 2015 to 2023 to reach US$ 19,227.8 ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):